Showing 4571-4580 of 4943 results for "".
- Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosishttps://practicaldermatology.com/news/20140609-valeant_pharmaceuticals_announces_fda_approval_of_jublia_for_the_treatment_of_onychomycosis/2459213/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole
- Allergan: Business As Usual Following New Valeant Offerhttps://practicaldermatology.com/news/20140606-allergan_business_as_usual_following_new_valeant_offer/2459215/At Allergan, executives say it is business as usual, even as the board reviews a hefty new offer from Valeant. Valeant last Friday increased its offer to Allergan by $14 per share, “subject to prompt good-faith discussions on a merger agreement.” The new bid values Allergan at about $180 a share and
- Cosmetic Surgery Forum Unveils 2014 Agendahttps://practicaldermatology.com/news/20140606-cosmetic_surgery_forum_unveils_2014_agenda/2459216/The agenda for the 2014 Cosmetic Surgery Forum was recently unveiled. The meeting will take place from December 3 through December 6 at the Palazzo Casino and Resort in Las Vegas, NV. Under course director Joel Schlessinger, MD, this year's meeting will include sessions on cosmetic treatments for me
- Allergan Comments on Pershing Square's and Valeant's Attempt to Remove a Majority of the Members of the Allergan Board of Directorshttps://practicaldermatology.com/news/20140602-allergan_comments_on_pershing_squares_and_valeants_attempt_to_remove_a_majority_of_the_members_of_the_allergan_board_of_directors/2459220/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today issued the following statement regarding the filing by Pershing Square Capital Management, L.P. ("Pershing Square") of preliminary proxy materials with the Securities and Exchange Commission ("SEC") in order to solicit proxies to call a
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- FDA to Require Warnings on Sunlamp Productshttps://practicaldermatology.com/news/20140530-fda_to_require_warnings_on_sunlamp_products/2459227/The FDA issued a final order reclassifying sunlamp products and ultraviolet (UV) lamps intended for use in sunlamp products from low-risk (class I) to moderate-risk (class II) devices. The order also requires that sunlamp products carry a visible black-box warning on the device
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- ALPHAEON Appoints Board Of Directorshttps://practicaldermatology.com/news/20140513-alphaeon_appoints_board_of_directors/2459240/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, appointed a team of prominent leaders in healthcare and business to its board of directors. The new board is comprised of experts from the healthcare industry, politics, science, and education. In addition, the
- Potential New Diagnostic Tools and Therapies for Melanoma in the Foreseeable Futurehttps://practicaldermatology.com/news/20140512-potential_new_diagnostic_tools_and_therapies_for_melanoma_in_the_foreseeable_future/2459241/Oregon State University researchers have identified a biochemical process that may cause normal and healthy skin cells to transform into cancerous melanoma cells. These findings could help predict melanoma exposure and could also lead to future treatments. Melanoma, the deadliest form of
- TetraLogic Pharmaceuticals Presents SHAPE at Annual Society of Investigative Dermatology Meetinghttps://practicaldermatology.com/news/20140506-tetralogic_pharmaceuticals_presents_shape_at_annual_society_of_investigative_dermatology_meeting/2459246/TetraLogic Pharmaceuticals Corporation presented results from the Phase I randomized, placebo-controlled clinical study of SHAPE (formerly SHP-141) in Stage IA -IIA Cutaneous T Cell Lymphoma (CTCL) at the annual Society of Investigative Dermatology Meeting, which was held in Albuquerque, New Mexi